Genomic profiling and drug screening for patients with aggressive blood cancers
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies: Next Generation Personal Hematology
This study is testing whether using genetic information and drug testing can help doctors choose better treatments for patients with aggressive blood cancers who have already tried several therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Vienna Academic / other |
| Locations | 1 site (Vienna) |
| Trial ID | NCT04470947 on ClinicalTrials.gov |
What this trial studies
This study aims to improve treatment decisions for patients with aggressive haematological malignancies by utilizing comprehensive genomic profiling and next-generation functional drug screening. Patients will be randomized into three groups, where treatment decisions will be guided by either genomic profiling, drug screening, or the physician's choice. The goal is to identify the most effective therapies based on individual tumor characteristics and previous treatment responses. This observational study will involve patients who have undergone multiple lines of therapy and have limited treatment options available.
Who should consider this trial
Good fit: Ideal candidates are patients suffering from aggressive haematological diseases who have received at least two lines of previous therapies and have limited treatment options.
Not a fit: Patients currently participating in another experimental clinical trial or those with a performance status that does not allow participation may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment options for patients with aggressive blood cancers.
How similar studies have performed: Other studies utilizing genomic profiling and functional drug screening have shown promise in personalizing treatment for cancer patients, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient is suffering from aggressive haematological disease AND has undergone at least two lines of previous therapies AND/OR has undergone at least one previous therapy and no standard treatment is available in the specific disease setting and disease specific guidelines recommend treatment in studies. * duration of last response is less than 6 months defined as first day of last treatment to date of relapse, the response duration has to be available with dates (dd/mm/yyyy) for initiation of and relapse to previous treatment. * best response to previous treatment has to be available. * The patient is able to give written informed consent and wishes to undergo further therapy * further therapy is medically feasible * tumor cell-containing samples can be obtained Exclusion Criteria: * current participation in another experimental clinical trial * performance status does not allow participation (ECOG ˃ 1) * pregnancy, tested at screening * patient suffers from classical or nodular, lymphocyte predominant Hodgkins lymphoma. * other malignoma, diagnosed \<1a before inclusion (except localized squamous cell carcinoma of the skin, surgically curable melanoma of the skin, basal cell carcinoma of the skin)
Where this trial is running
Vienna
- Medical University of Vienna — Vienna, Austria (Recruiting)
Study contacts
- Study coordinator: Philipp B. Staber, MD, PhD
- Email: philipp.staber@meduniwien.ac.at
- Phone: +43 140400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.